What is Chardan Capital’s Forecast for MNMD FY2025 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a research report issued on Monday, March 24th. Chardan Capital analyst R. Li expects that the company will earn ($1.70) per share for the year. Chardan Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the prior year, the business posted ($0.59) EPS.

Other analysts have also recently issued research reports about the company. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 target price for the company. Robert W. Baird decreased their price objective on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Finally, Oppenheimer restated an “outperform” rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Ten equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Trading Down 2.9 %

Mind Medicine (MindMed) stock opened at $6.58 on Thursday. Mind Medicine has a 52 week low of $5.03 and a 52 week high of $12.22. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. The firm has a market capitalization of $495.92 million, a price-to-earnings ratio of -2.91 and a beta of 2.57. The company has a 50 day moving average price of $7.28 and a 200 day moving average price of $6.96.

Insider Transactions at Mind Medicine (MindMed)

In related news, insider Daniel Karlin sold 6,836 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the completion of the sale, the insider now directly owns 446,177 shares in the company, valued at approximately $3,007,232.98. This represents a 1.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert Barrow sold 21,208 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $142,941.92. Following the transaction, the chief executive officer now directly owns 856,556 shares in the company, valued at $5,773,187.44. The trade was a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock worth $204,835 in the last 90 days. 2.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. boosted its position in Mind Medicine (MindMed) by 39.9% during the fourth quarter. AWM Investment Company Inc. now owns 1,193,162 shares of the company’s stock worth $8,304,000 after purchasing an additional 340,162 shares during the period. Marshall Wace LLP boosted its holdings in shares of Mind Medicine (MindMed) by 9.3% during the 4th quarter. Marshall Wace LLP now owns 2,501,391 shares of the company’s stock worth $17,410,000 after buying an additional 213,526 shares during the period. Tang Capital Management LLC bought a new stake in shares of Mind Medicine (MindMed) during the 4th quarter worth $1,392,000. Geode Capital Management LLC grew its stake in Mind Medicine (MindMed) by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock valued at $9,548,000 after buying an additional 162,933 shares during the last quarter. Finally, Allostery Investments LP bought a new position in Mind Medicine (MindMed) in the 4th quarter worth $905,000. 27.91% of the stock is owned by institutional investors.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.